Deucravacitinib

Molecular mass: 425.467 g/mol  PubChem compound: 134821691

Therapeutic indications

Deucravacitinib is indicated for:

Moderate to severe plaque psoriasis

Population group: only adults (18 years old or older)

Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Psoriatic arthritis

Population group: only adults (18 years old or older)

Deucravacitinib, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Deucravacitinib is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

Clinically important active infections

Infectious disease

Tuberculosis infection

Tuberculosis

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2026: SOTYKTU Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈